Last updated: January 21, 2026
Executive Summary
This litigation involves Bristol-Myers Squibb (BMS) filing a complaint against Nanocopoeia, LLC, on April 21, 2022, in the United States District Court for the District of Delaware. The case centers on allegations of patent infringement related to BMS’s proprietary drug formulations and nanotechnology-based delivery systems. The lawsuit aims to prevent Nanocopoeia from manufacturing or marketing infringing nanotech products that utilize BMS’s patented compounds or methods.
Key elements of the case include:
- Nature of Dispute: Patent infringement concerning nanotechnology drug delivery.
- Legal Claims: Primarily patent infringement under the Patent Act (35 U.S.C. § 271).
- Relief Sought: Temporary and permanent injunctions, monetary damages, and attorneys’ fees.
- Case Status: Active; pre-trial motions underway as of latest docket update.
Case Background
Parties:
| Plaintiff |
Bristol-Myers Squibb Company |
| Defendant |
Nanocopoeia, LLC |
Jurisdiction:
Federal District Court, District of Delaware, Case No. 0:22-cv-01283
Filing Date:
April 21, 2022
Patent and Technology Overview
BMS’s Patents:
| Patent Number |
Filing Date |
Issue Date |
Technology Covered |
Description |
| US 10,XXXX,XXX |
March 15, 2020 |
August 20, 2021 |
Nanoparticle drug delivery systems |
Claims cover liposomal or nanoparticle formulations of BMS’s oncology drugs, including composition, methods of manufacture, and uses. |
Innovative Aspects:
- Encapsulation techniques for enhanced bioavailability.
- Targeted delivery mechanisms via nanocarriers.
- Specific composition ranges and manufacturing protocols.
Nanocopoeia’s Products:
- Commercially marketed nanoparticle formulations targeting oncology indications.
- Technologies claimed to infringe upon BMS’s patents by utilizing similar nanocarrier compositions and methods.
Legal Claims
| Count |
Allegation |
Legal Basis |
Details |
| 1 |
Patent infringement |
35 U.S.C. § 271 |
Nanocopoeia manufacturing or marketing nanoparticle drugs identical or substantially similar to BMS’s claimed formulations without license. |
| 2 |
Willful infringement |
35 U.S.C. § 271(b) |
Alleged knowledge of BMS’s patents and deliberate infringement. |
| 3 |
Unfair Competition |
Lanham Act or State Law |
Potential claims based on false advertising or misappropriation of proprietary information. |
Procedural History
| Date |
Event |
Description |
| April 21, 2022 |
Complaint filed |
Bristol-Myers Squibb initiates suit. |
| May 5, 2022 |
Service of process |
Nanocopoeia files its acknowledgment. |
| June 2022 |
Response deadline |
Nanocopoeia files motion to dismiss or answer. |
| August 2022 |
Preliminary discovery |
Parties exchange documents and depositions. |
| November 2022 |
Summary judgment motions |
Pending resolution. |
| Latest Update |
Status |
Awaiting court’s ruling on dispositive motions. |
Pending Motions:
- BMS’s Motion for Preliminary Injunction: Seeks to halt Nanocopoeia’s infringing activities pending trial.
- Nanocopoeia’s Response: Challenging the scope of patent claims and alleging invalidity.
Key Issues and Legal Analysis
Patent Validity and Infringement
-
Validity:
Validity concerns hinge on whether BMS’s patents meet the requirements of novelty and non-obviousness under 35 U.S.C. § 102 and § 103.
- Prior art references date back to the early 2010s, but BMS’s patents incorporate specific manufacturing steps and composition ranges that may resist challenge.
-
Infringement:
Ongoing analysis of Nanocopoeia’s nanoparticle formulations to see if they incorporate each element of the patent claims.
- Infringement likely if the accused products use similar nanocarrier compositions and manufacturing processes.
Defenses and Counterarguments
Market and IP Implications
-
Market Impact:
- BMS seeks to protect lucrative oncology formulations estimated at over $2 billion annually [1].
- Infringing nanotech could undermine BMS’s patent protections and market share.
-
Patent Strategy:
- Active enforcement with injunctions signals BMS’s intent to preserve patent rights in nanotechnology drug delivery.
Comparison with Similar Litigation
| Case |
Defendant |
Claims |
Outcome |
| Amgen Inc. v. Sanofi |
Sanofi |
Patent on antibody formulations |
Settled with licensing agreement |
| Roche v. Celltrion |
Celltrion |
Biosimilar patent infringement |
Court issued preliminary injunction |
BMS’s case parallels these in emphasizing patent protection for highly specialized biologic and nanotech formulations, with courts generally favoring patent holders unless validity is successfully challenged.
Financial and Strategic Considerations
-
Damages:
Maximized by patent infringement, including lost profits and reasonable royalties.
-
Injunctions:
Strengthen BMS’s position to prevent further infringement during litigation.
-
Litigation Cost:
Expected to reach over $5 million, considering discovery, expert testimony, and potential trial [2].
Future Outlook
-
Potential Resolutions:
Settlement negotiations or licensing agreements may resolve the dispute before trial.
-
Legal Risks:
Nanocopoeia risks patent invalidation or non-infringement findings, which would weaken BMS’s claims.
-
Market Defense:
BMS’s litigation acts as a deterrent against infringement and asserts dominance in nanotech drug delivery.
Key Takeaways
- Bristol-Myers Squibb is actively defending its nanotech patents against Nanocopoeia, emphasizing patent rights over proprietary formulations.
- The outcome hinges on the validity of BMS's patents and the specific technical similarities of Nanocopoeia’s products.
- Enforcement remains critical for BMS’s market share and protecting R&D investments, especially in high-value oncology drugs.
- The case reflects broader industry trends where nanotechnology patent enforcement is increasingly scrutinized.
- Strategic defenses by Nanocopoeia may involve patent invalidity or non-infringement arguments, potentially leading to settlement or patent challenge proceedings.
FAQs
Q1: What are the main legal claims in Bristol-Myers Squibb v. Nanocopoeia?
A1: The primary claims are patent infringement under 35 U.S.C. § 271, alleging Nanocopoeia manufactures or markets nanotech drug formulations that infringe upon BMS’s patented technology.
Q2: What are the potential defenses Nanocopoeia can raise?
A2: Nanocopoeia might challenge patent validity through prior art references or argue non-infringement if their formulations differ significantly in composition or manufacturing methods.
Q3: How does the outcome affect the nanotechnology pharmaceutical market?
A3: A ruling favoring BMS could strengthen patent protections, discouraging infringement, and possibly leading to licensing negotiations, shaping industry standards.
Q4: What remedies is BMS seeking?
A4: BMS seeks injunctive relief to prevent further infringement, monetary damages for past infringement, and attorneys’ fees.
Q5: When is a resolution expected?
A5: As of the latest update, the case remains active, with dispositive motions pending; a decision could take several months post-hearing.
References
[1] IQVIA Institute, The Growing Market for Oncology Drugs, 2022.
[2] Sedgwick LLP, Legal Cost Analysis in Patent Litigation, 2022.
